Page last updated: 2024-09-04

cox 189 and Liver Diseases

cox 189 has been researched along with Liver Diseases in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Kalbag, J; Lasseter, K; Milosavljev, S; Oberstein, S; Rordorf, C; Yeh, CM	1
Choi, L; Mangold, JB; Marshall, P; Rordorf, CM	1

Reviews

1 review(s) available for cox 189 and Liver Diseases

Article	Year
Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. Clinical pharmacokinetics, 2005, Volume: 44, Issue:12 Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Kidney Diseases; Liver Diseases; Organic Chemicals; Osteoarthritis	2005

Other Studies

1 other study(ies) available for cox 189 and Liver Diseases

Article	Year
No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor. Pharmacological research, 2004, Volume: 50, Issue:2 Topics: Administration, Oral; Area Under Curve; Bilirubin; Case-Control Studies; Cyclooxygenase Inhibitors; Diclofenac; Drug Administration Schedule; Female; Half-Life; Humans; Liver Diseases; Male; Middle Aged; Organic Chemicals; Prothrombin Time; Serum Albumin; Switzerland; Tablets; Time Factors; Treatment Outcome	2004

Article

Year

No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor.

Pharmacological research, 2004, Volume: 50, Issue:2

Topics: Administration, Oral; Area Under Curve; Bilirubin; Case-Control Studies; Cyclooxygenase Inhibitors; Diclofenac; Drug Administration Schedule; Female; Half-Life; Humans; Liver Diseases; Male; Middle Aged; Organic Chemicals; Prothrombin Time; Serum Albumin; Switzerland; Tablets; Time Factors; Treatment Outcome

2004